ProMIS Neurosciences Inc. ("ProMIS Neurosciences" or, the "Company") (formerly, Amorfix Life Sciences Ltd.), announces that it has effected its name change to ProMIS Neurosciences Inc. on July 8, 2015 and shares will begin trading under the new name on July 14, 2015

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TSX: AMF

TORONTO, July 14, 2015 /CNW/ - The common shares of the Company will commence trading on the Toronto Stock Exchange under the new name "ProMIS Neurosciences Inc." and the new stock symbol "PMN" at the opening of trading on July 14 2015.  The new CUSIP number is 74346M109 and the new ISIN number is CA 74346M1095.

About ProMIS Neurosciences Inc.
Harnessing the power of precision medicine to conquer Alzheimer's disease.
The company's mission is to discover and develop precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
ProMIS Neurosciences utilizes its computational discovery platform, ProMIS^TMto predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this 'Precision Medicine' approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. ProMIS Neurosciences has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection^TM and AMFIA^TM, an ultra-sensitive dual-bead immunoassay. In addition, Amorfix owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE ProMIS Neurosciences Inc.

Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel: [phone], Fax: [phone], [email protected]; Warren Whitehead, Chief Financial Officer, ProMIS Neurosciences Inc., Tel: [phone], Fax: [phone], [email protected]